Report Code: A14826 | Pages: NA | Mar 2023 | 795 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Quinolones Market
Request Now !Quinolone is a major class of antibacterial drug. Quinolones or fluoroquinolones are synthetic antibacterial drugs that show a specific function of inhibiting the nucleic acid synthesis. Depending on their bactericidal properties, quinolones are efficient against bacterial infections of the sinuses, lungs, skin, stomach, and urinary tract. These drugs can interfere with the human DNA synthesis, as humans have the same basic nucleic acid constituents as those of the bacteria. Quinolones exhibit rapid bactericidal activity, wherein they easily infiltrate the bacterial cell membrane and reach the DNA where they bind to bacterial topoisomerases such as DNA gyrase, thus inhibiting the bacterial nucleic acid synthesis. The most extensively used quinolones are norfloxacin and ciprofloxacin Other crucial quinolones include ofloxacin, enoxacin, lomefloxacin, levofloxacin, trovafloxacin, and gatifloxacin.
COVID-19 Impact analysis
The COVID-19 virus outbreak in December 2019, the World Health Organization announced it a public health emergency. The disease has spread to over 100 countries and affected huge losses of lives around the globe.
Particularly the global manufacturing, pharmaceutical, tourism, and financial markets have been hit hard. The outbreak of the pandemic has added risk factors to the already weak growth of the world economy. The descending pressure on the world economy that once showed signs of improvement in the previous period has improved again.
The negative global impacts of the COVID-19 are already there, substantially affecting the quinolone market in the coming years, and this factor is expected to have a significantly negative impact on the revenue growth of this industry.
Top Impacting Factors
Market Trends
New product launches to flourish the market
In January 2018, Melinta Therapeutics, Inc. introduced Baxdela (delafloxacin), which is an oral fluoroquinolone used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The launch of Baxdela offers new treatment option and company’s growth in the infection therapeutics area.
In September 2019, KYORIN Holdings, Inc. acknowledged an approval from the Japan’s Ministry of Health, Labour and Welfare for the drug Lasvic (lascufloxacin hydrochloride), which is a novel quinolone antibacterial drug specified as a first-line monotherapy to treat community-acquired respiratory and ENT infections. The approval of Lasvic is important milestone for the company to address the growing threat of antimicrobial resistance and provide effective treatment options for patients.
Key Benefits of the Report
Questions Answered in the Quinolones Report
Quinolones Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Application |
|
By End User |
|
By Region |
|
Key Market Players | Bayer AG, Novartis AG., Sanofi, Johnson & Johnson, Merck & Co, Inc., LG Life Sciences, Allergan, Inc. |
Loading Table Of Content...
Start reading.
This Report and over 19,649+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers